Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Viable Bifidobacterium for Feeding Intolerance in Preterm Infants
NCT02060084Phase 4Completed
- Sponsor
- Wang Hua
- Start
- Jan 2014
- Primary completion
- Dec 2014
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bifidobacterium triple viable in feeding intolerance (3 arms), sponsored by Wang Hua. Primary endpoint: Intestinal flora composition and distribution at 1 week. Started Jan 2014; status: completed.
02
Drugs
bifidobacterium triple viable
03
Conditions
feeding intolerance
Beyond the preview
Go deeper on NCT02060084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02060084.